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ABSTRACT
Neurodegenerative diseases are cluster of disorders arising from neuronal cell death in the central nervous system. Its 
prevalence increases with increasing age. Therapeutic options for neurodegenerative disease include protection against 
oxidative damage, attenuation of neuroinflammation, maintenance of essential neurotransmitters, and protection against 
environmental factors that induce neurotoxicity. Honey with its antioxidative, anti-inflammatory, and cytoprotective effects 
is a potential candidate for therapy in neurodegenerative diseases. The present evidence-based review summarizes the 
effects of honey on neurodegenerative diseases in non-human subjects. Three electronic databases, namely PubMed, 
Ovid Medline and Scopus were searched for records published from inception of database to May 2020 to identify 
reports on the association of honey and neurodegenerative diseases. Based on the preset eligibility criteria, 8 qualified 
articles were selected and discussed in this review. Honey from different geological origin around the globe was used by 
different researcher among the studies included. Honey confers protection against oxidative stress induced by hypoxia 
and metabolic syndrome, aluminium toxicity, and neuroinflammation. Honey also demonstrated potential ability to inhibit 
neurotransmitters degrading enzymes and restore memory impairment. This review showed a sparse body of evidence 
on the potential of honey as neurodegenerative disease therapy.
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ABSTRAK
Penyakit neurodegeneratif adalah satu kumpulan penyakit yang muncul daripada kematian sel saraf di dalam sistem 
saraf pusat. Prevalens penyakit neurodegeneratif meningkat dengan peningkatan usia. Antara strategi rawatan penyakit 
ini adalah perlindungan daripada kerosakan oksidatif, pengawalan keradangan saraf, pemeliharaan neuropemancar 
penting dan perlindungan daripada faktor persekitaran yang boleh mengakibatkan ketoksikan saraf. Madu dengan 
kesan antioksida, anti-keradangan dan perlindungan sito merupakan calon yang berpotensi untuk perawatan penyakit 
neurodegeneratif dalam subjek bukan manusia. Tiga pengkalan data, PubMed, Ovid Medline dan Scopus digunakan 
untuk mengenal pasti rekod yang diterbitkan daripada permulaan pangkalan data sehingga Mei 2020 yang melaporkan 
kaitan madu dan penyakit neurodegeneratif. Berdasarkan kriteria yang ditetapkan, 8 artikel yang bersesuaian dipilih 
dan dibincangkan dalam kajian ini. Madu daripada punca geografi yang pelbagai di serata dunia telah digunakan 
oleh pengkaji yang berbeza disertakan dalam kajian ini. Madu menunjukkan perlindungan ke atas penyakit 
neurodegeneratif melalui perlindungan daripada tekanan oksida yang dihasilkan oleh kekurangan oksigen dan sindrom 
metabolik, perlindungan daripada ketoksikan aluminium dan perlindungan daripada keradangan saraf. Madu turut 
menunjukkan kebolehan untuk mencatutkan enzim penguraian neuropemancar dan memulihkan kehilangan memori. 
Kajian ini menunjukkan jurang pengetahuan dalam penggunaan madu untuk rawatan penyakit neurogeneratif.
Kata kunci: Antioksida; kehilangan memori; madu; penjanaan semula; penyakit neurodegeneratif
INTRODUCTION
NEURODEGENERATIVE DISEASES
Neurodegenerative disease is a cluster of disorders that 
arise as a consequence of neuronal death in the different 
parts of the brain, particularly the central nervous system 
(CNS) (Berman & Bayati 2018). Neurodegenerative 
diseases include Alzheimer’s disease (AD), Parkinson’s 
disease (PD), Huntington’s disease (HD), or amyotrophic 
lateral sclerosis (ALS). 
Since these different parts of the brain controls 
different functions, each disease has a unique clinical 
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manifestation. For instance, Parkinson’s disease, 
Huntington’s disease and ALS are diseases that arise 
from neurodegeneration of the brain area that control 
movement, resulting in the inability to control movement. 
In Alzheimer’s disease, a more disperse degeneration in 
the cerebral cortex resulted in loss of memory (Ahmad et 
al. 2017). 
Neurodegenerative disorders manifested mainly in 
the elderly. The annual incidence of Alzheimer’s disease 
(AD) has been shown to increase exponentially with 
advancing age (Haines 2018; Rubenstein et al. 2019). 
Similarly, incidence of Parkinson’s disease (PD), the second 
most common age-related neurodegenerative condition 
also increases with age (Lee & Gilbert 2016; Simon et al. 
2020). Hence, ageing is considered as the most important 
risk factor for the development of neurodegenerative 
diseases (Kritsilis et al. 2018).
A long-standing hypothesis on the age-related 
pathophysiology is the slow and progressive accumulation 
of oxidative damage to macromolecules throughout the 
life span of an organisms (Schöttker et al. 2015; Speakman 
& Selman 2011). Empirical evidences of oxidative stress 
as contributing factor in development of various disease 
has been well-established, including the neurodegenerative 
diseases (Chen et al. 2020; Nogueira et al. 2020; Shokr et 
al. 2020). Oxidative stress can induce cellular senescence 
within the neurons, the state where the neuron remains 
viable and metabolically active but may not perform its 
normal physiological function (Baker & Petersen 2018; 
Martinez-Cue & Rueda 2020). Hence, antioxidative 
agent may be potentially beneficial in the development of 
neurodegenerative therapy.
Amyloid plaque and neurofibrillary tangle, are 
two macromolecule abnormalities that define AD 
pathogenesis. Both phenomena were reported to exert a 
prion-like effect on the neuron following accumulation of 
misfolded amyloid beta (Aβ) peptide in amyloid plaque 
and phosphorylation of tau protein in neurofibrillary tangle 
(Hu et al. 2020; Malek-Ahmadi et al. 2019; Sakakibara et 
al. 2019; Wu et al. 2020). Thus, targeting the inhibition of 
the amyloid plaque and neurofibrillary tangle in neuron 
are of paramount importance in AD therapy development.
Neurotransmitter is the chemical messenger which 
transmits signals across two adjacent neurons via a 
chemical synapse. The signal can either be excitatory or 
inhibitory and regulated by the mechanisms that either 
produce or degrade the neurotransmitter molecules. In 
AD pathology, reduced level of acetylcholine resulted 
in the impairment of memory formation (Moreira et al. 
2017). The decreased level of acetylcholine is attributed 
to the increase activity of acetylcholinesterase (AChE), the 
enzyme responsible to degrade the excess acetylcholine 
after the completion of its signal transduction. Hence, 
inhibition of the AChE activity is an important target in 
the AD pathogenesis (Rosengarten et al. 2006; Torvinen-
Kiiskinen et al. 2014). Similarly, inhibition of monoamine 
oxidase that degrades norepinephrine, has also been 
targeted in the AD pathogenesis (Schedin-Weiss et al. 2017; 
Yanez & Vina 2013).
Furthermore, available evidences also suggest that 
many neurodegenerative diseases are not merely the 
diseases of dying neurons (Hemonnot et al. 2019; Marlatt 
et al. 2014; Mullard 2018; Sierksma et al. 2020; Taipa 
et al. 2018). Involvement of non-neuronal cells in the 
brain, which are even more abundant in the CNS than 
neurons, has been reported in the neurodegenerative 
pathogenesis. The presence of activated microglial cells, 
the immune cells of the brain, in neurodegenerative 
tissue, suggested the involvement of neuroinflammation 
in neurodegeneration. Elucidating these neuron-glial 
interactions will empower the understanding of the neurons 
non-autonomous disease mechanisms.
T h e  r o l e  o f  e n v i r o n m e n t a l  f a c t o r s  i n 
neurodegenerative disease has gained significant interest 
among biomedical scientist in the last few decades (Chin-
Chan et al. 2015; Groves-Kirkby et al. 2016; Maher 2019; 
Spencer et al. 2016). The late onset of these disease in the 
elderly is believed to be due to the prolong exposure to risk 
factors that occurred years or decades before its diagnosis. 
In cellular experimental models, neurotoxic metals such 
as lead, mercury, aluminium, cadmium and arsenic, as well 
as some pesticides and metal-based nanoparticles have 
been involved in AD due to their ability to increase Aβ 
peptide and the phosphorylation of tau protein (Chin-Chan 
et al. 2015). Thus, an agent that can protect the neuron 
from the adverse effect of environmental factors exposure 
is relevant to the therapy of neurodegenerative diseases.
HONEY PHYTOCHEMICALS
Honey is a natural sweetener solution produced by the 
bee from either the nectar of plants, the secretions of 
living parts of plants, or the excretions of plant sucking 
insects on the living parts of plants. The aforementioned 
raw materials are collected and transformed into honey 
by combining them with specific substances of their own 
before being deposited, dehydrated, stored and left to be 
ripen and matured in the honey comb (CAC 2001). 
It is made up of approximately 80% carbohydrate 
(35% glucose, 40% fructose, and 5% sucrose) and 20% 
water. About 180 different substances inclusive of amino 
acids, vitamins and minerals have been reported to be 
contained in honey (Kumar et al. 2018). A consensus from 
a comprehensive review on honey composition showed 
that honey contains approximately 1.13% proteins, 0.36% 
minerals, 215.2 mg/g lipid, 15.5 mg/kg hydroxymethyl 
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furfural, 13.2 mg/g vitamin C, 8.57 milliequivalents/
kg lactone and 873.3 mg/kg proline content. Among the 
major minerals that are known to be detected in honeys 
are sodium, potassium, calcium, magnesium, lead, sulfur, 
and chloride (Solayman et al. 2016).
HONEY AND NEURODEGENERATIVE DISEASES
The beneficial effect of honey on human health derives 
mainly from its content in phenolic compounds (Cianciosi 
et al. 2018). Among phenolic compounds reported in honey 
are chrysin, apigenin, pinobanksin, pinocembrin, and 
caffeic acid (Cheung et al. 2019). Honey in many forms, 
whether as crude solution, hydrophilic or hydrophobic 
extracts, has been reported to possess antioxidative (Chua 
et al. 2013), anti-inflammatory (Minden-Birkenmaier et 
al. 2019), and cytoprotective effects in a plethora of cells 
(Nordin et al. 2018). In this review, a systematic search 
of the literature was conducted to identify and discuss 
all available current evidence that report the association 
of honey and neurodegenerative diseases in non-human 




Electronic database search was conducted to identify 
relevant studies reporting the therapeutic effects of honey 
or its constituent on neurodegenerative disease. 
Databases involved include PubMed, Ovid Medline, 
and Scopus. The search was not limited by time and 
include all records published from the inception of each 
database to May 2020. Keywords used were honey AND 
(neurodegenerative disease OR Alzheimer’s disease 




Literature findings were screened by two independent 
reviewers in a four stages process. First, any duplicate 
records found in the three databases were removed. 
Then, any articles that can be categorized as secondary 
literatures such as but not limited to review articles, 
editorials, news, letter, or book source were excluded. 
Next, primary literatures that were not related to honey or 
neurodegenerative disease based on title and abstract were 
excluded. Finally, full text articles were read through and 
selected according to the inclusion and exclusion criteria 
outlined.
INCLUSION CRITERIA
Original research articles (in vitro, in vivo or clinical 
study) that discuss the effect of honey or its bioactive 
compounds on neurodegeneration pathology published in 
English language.
EXCLUSION CRITERIA
Secondary literature (review articles, newsletter, or book 
chapter), not published in English language, studies that 
used synthetic compound not originally derived from 
honey, and studies that used bee propolis instead of its 
honey.
DATA MANAGEMENT
Data extraction was performed independently with the 
use of a data extraction form. The following data were 
recorded from the studies: The experimental model or study 
population used; type or form of honey or its constituent 
used; the outcome measures; a brief description of the 
results of the study; and the conclusion of the study.
RESULTS
ELECTRONIC DATABASE FINDINGS
The keyword search yielded a sum of 158 potential 
records across the three databases. Of this, 52 duplicate 
records from the three databases were removed. Then, 
46 review articles and 1 conference proceedings 
were excluded from the screening process. From the 
title and abstracts, 51 articles were excluded from the 
screening process due to being not related to honey or 
any neurodegenerative disease parameter. Following our 
inclusion and exclusion criteria, all of the remaining 8 
articles were eligible to be included in the review. All data 
were extracted directly from the articles. A flow chart of 
the selection process including reasons for exclusion is 
shown in Figure 1.
STUDY CHARACTERISTICS
The summary of the characteristics of all studies is 
displayed in Table 1. All studies included in the review 
were published between the year 2011 and 2020. In 
terms of honey used, each included study used different 
honey coming from diverse geographical origin, namely 
Algeria (Zaidi et al. 2019), Italy (Candiracci et al. 2012), 
Malaysia (Arshad et al. 2020; Saxena et al. 2014; Wan et 
al. 2020), Poland (Baranowska-Wojcik et al. 2020), Saudi 
Arabia (Shati et al. 2011) and Turkey (Yildiz et al. 2014).
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TABLE 1. Studies summary of the effect of honey in cardiovascular diseases
In vitro studies












1. Phenolic content ranges from 
0 1267.96 mg GAE/100 g 
(H1) to 33.73 mg GAE/100 
g (H26)
2. AChE inhibition ranges from 
39.51% (H1) to 1.09% (H16)
3. Butyrylcholinesterase 
inhibition ranges from 
39.76% (H6) to 3.06% (H20)
Honeys can be 
considered
as a possible source 
of cholinesterase 
inhibitors





















1. Flavonoid content ranges 
from 0.29 (H29) to 2.25 (H4) 
mg CE/ 100 g
2. DPPH inhibition ranges from 
4.41 (H2) to 83.93 (H4) %
3. ABTS inhibition ranges from 
2.52 (H2) to 63.24 (H4) %
4. Anti-inflammatory activity 
ranges from 0 (H2, H8, H10, 
H11, H22) to 85.33 (H27) %
5. AChE inhibition ranges from 
20.69 (H20) to 76.04 (H9) %
6. α-glucosidase inhibition 









158 records identified: 
83 identified from PubMed 
22 identified from Ovid Medline 













Duplicate records removed: 52 
106 records identified for screening after 
duplicates removed  
Removal of records that are: 
- Review articles: 46 
- Conference proceedings: 1 







Removal of articles not relevant to honey or any 






8 full text articles read thoroughly  
8 articles included in the data synthesis 
FIGURE 1. Flow chart of study selection procedure
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1. MOA inhibition into 
half activity
2. Total phenolic 
content
3. Ferric reducing 
power
For honey, pollen and propolis
1. Concentrations that inhibited 
MOA into half activity were 
41.60, 30.56, and 24.95 µg/
mL, respectively
2. Total phenolic content was 
0.98, 52.12, and 89.51 mg 
GAE/g, respectively
3. Ferric reducing power were 
24.11, 124.62, and 509.86 
Trolox/g, respectively
Chestnut honey, 
pollen and propolis 
can inhibit 
monoamine oxidase 
that is known to 
















2. Cytokines gene 
expression
3. ROS production
Supplementation of honey 
flavonoids
1. Does not induce cytotoxicity 
in N13 cells
2. Attenuates LPS-induced 
cytokine expression






activation in the 
brain
In vivo studies
Author Experimental model Type of honey Outcome measures Result Conclusion











HCHF at the 
last 35 days of 
the 16 weeks 
treatment
1. Serum fasting blood 
glucose
2. Open field test
3. Morris water maze
4. Nissl staining of the 
hippocampus
1. Decreased in the KH group 
compared to metabolic 
syndrome group
2. KH group exhibits less 
anxious behavior compared 
to metabolic syndrome group
3. KH group demonstrated 
improved spatial memory 
compared to metabolic 
syndrome group
4. Pyramidal hippocampal cells 
were greater in KH compared 















to rats, 200 mg/
kg daily for 14 
days
1. Morris water maze
2. Novel object 
recognition
1. LPS-induced impairment of 
spatial memory restored with 
Tualang honey
2. LPS-induced impairment of 
recognition memory restored 
with Tualang honey 











ligation to induced 
neurodegeneration
Tualang honey 
fed to rats, 1.2 
g/kg daily for 






1. Tualang honey preserved the 
compact structure of CA1 
stratum pyramidal with less 
pyknotic nuclei














honey daily for 
45 days (Aseer, 
Saudi Arabia).
1. Antioxidant enzyme 
activities
2. Serum tumor markers
3. Gene expression
Supplementation of honey 
1. Alleviates the reduction in 
antioxidant activity induced 
by aluminum
2. Inhibits the increase of 
tumor markers induced by 
aluminum
3. Up-regulated BCL-W, 









With regard to the type of studies, four in vitro studies 
and four in vivo studies were retrieved. The in vitro studies 
can be further categorized into cell-free biochemical 
assay, ex vivo enzymatic assay and cellular model. The 
two studies that included the cell-free assay tested their 
honey on cholinesterase, an important enzyme involved 
in the neurodegenerative pathology (Baranowska-Wojcik 
et al. 2020; Zaidi et al. 2019). The ex vivo enzymatic 
assay involved testing honey effect on the activity of 
monoamine oxidase isolated from the mitochondria of rat 
liver (Yildiz et al. 2014). The cellular model study utilizes 
lipopolysaccharide (LPS)-induced N19 microglial cells 
to model neuroinflammation in the brain (Candiracci et 
al. 2012).
There were four in vivo studies included, using 
mice and rats induced with plethora of factors. 
Neurodegeneration effect in rats was induced with 
cerebral hypoperfusion via ligation of the bilateral 
common carotid arteries (Saxena et al. 2014), LPS-induced 
inflammation (Wan et al. 2020), and high carbohydrate 
high fat (HCHF) diet-induced metabolic syndrome (Arshad 
et al. 2020). Meanwhile, the mice were injected with 
aluminium chloride to investigate protective effect of 
honey against aluminium-neurotoxicity (Shati et al. 2011).
NEUROPROTECTIVE EFFECT OF HONEY AGAINST 
ENVIRONMENTAL FACTORS OF NEUROGENERATIVE 
DISEASE
The increasing utility of aluminium as a vessel for food 
storage has been associated with neurodegenerative 
diseases such as Alzheimer’s disease (Bondy 2016). 
Aluminium toxicity has been known to affect several 
enzymes and other molecules relevant to the disease 
pathology (Di Paolo et al. 2014). This prompt Shati et al. 
(2011) to produce the first report that linked the supplement 
of honey to neurodegenerative disease. They investigated 
the protective effect of feeding their aluminium -induced 
mice with honey obtained from Aseer, Saudi Arabia. 
Indeed, the honey supplementation exhibited protection 
from the impaired antioxidant capacity and elevation of 
tumor markers caused by the aluminium toxicity in mice 
brain (Shati et al. 2011).
PROTECTIVE EFFECTS OF HONEY AGAINST CEREBRAL 
HYPOPERFUSION INDUCED NEURODEGENERATION
The brain uses approximately 20% of available oxygen 
for normal function, making tight regulation of blood flow 
and oxygen delivery critical for survival. Reduced cerebral 
blood flow, has been associated with neurodegenerative 
disease such as Alzheimer and dementia due to elevation 
of the cellular oxidative stress (Zhao & Gong 2015). 
Saxena et al. (2014) reported the protective effect of 
Tualang honey in rats with cerebral hypoperfusion-induced 
neurodegeneration. By introducing permanent bilateral 
common carotid arteries ligation in rat’s brain, the 
hippocampal cells became damaged, distorted, irregular 
cells with shrunken cytoplasm and dark pykonotic 
nuclei. In the honey supplemented rats, the hippocampal 
cells remain normal despite undergoing the same 
procedure (Saxena et al. 2014).
PROTECTIVE EFFECTS OF HONEY AGAINST 
NEUROINFLAMMATION INDUCED DEGENERATION
Neuroinflammation has been considered as major 
contributor in the neurodegenerative disease pathology. 
Excessive release of the inflammatory molecules such as 
IL-1β, TNF-α, NO, and reactive oxygen intermediates 
(ROS) by the activated microglia cells, the immune cells 
of the brain, has been reported to be linked with neuronal 
death in the neurodegenerative process.
Leveraging their lipopolysaccharide (LPS)-
induced N13 microglia cells, Candiracci et al. (2012) 
reported the protective effect of honey flavonoids against 
neuroinflammation. Honey ameliorate the deleterious 
effects associated with microglial activation in the 
brain. The flavonoids were extracted from the Italian 
multifloral honey (Candiracci et al. 2012).
INHIBITORY EFFECTS OF HONEY ON THE ENZYMES 
RELEVANT TO NEURODEGENERATIVE DISEASE
Inhibition of the monoamine oxidase (MAO) is an 
important pharmacological process in the treatment of 
Alzheimer and Parkinson’s diseases. Yildiz et al. (2014) 
investigated the MAO inhibition effect of the Chestnut 
honey, pollen and propolis from the Black Sea region 
in Turkey. All three of the bee product inhibited MAO 
activity. Propolis exhibited the strongest inhibition 
followed by pollen and finally honey. Antioxidant capacity 
and phenolic content of the bee products have the similar 
pattern with propolis being the strongest and honey being 
the weakest antioxidants. Based on the results, they 
hypothesized that the MAO inhibition might have a direct 
relationship with the phenolic content with each individual 
bee product (Yildiz et al. 2014).
Another important enzyme in the neurodegenerative 
disease pathology is the cholinesterase. In Alzheimer’s 
disease, low level of acetylcholine, the neurotransmitter 
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essential for processing memory and learning, is a well-
documented occurrence contributing to its pathology. The 
reduced level of the neurotransmitter is the result of the 
overactivity of acetylcholinesterase (AChE), the enzyme 
responsible to degrade excess acetylcholine in the neurons. 
As such, one of the targets of AD treatment is to increase 
the level of acetylcholine in the brain by inhibiting the 
AChE. 
Zaidi et al. (2019) investigated the effect of 31 
Algerian Honey on the inhibition of AChE. For the 
polyfloral honeys, the inhibition of AChE ranged from 
20.69 (H20) to 76.04% (H9) and from 39.89 (H6) to 
67.15% (H19) for monofloral honeys. Sample H9 had 
the best AChE inhibition and the results obtained was 
significantly different from the others. They concluded 
that all of their honey samples were able to inhibits AChE 
and the effects varied according to the geographical and 
floral origin of the honey.
Similarly, Baranoswka et al. (2020) investigated 
the effect of 47 Polish honey on the inhibition of AChE 
as well as the less specific choline ester enzymes, 
butyrylcholinesterase. They also found a variation of 
effects according to the floral origin of their honey. In 
this study, the highest AChE inhibition (39.51%) was 
observed in buckwheat honey and the lowest (1.09%) was 
found in multi-floral honey. The highest AChE inhibition 
by buckwheat honey might be attributed to its phenolic 
content which also reported to be the highest among all 
honey. Some honeys showed no AChE inhibition at all. 
For butyrylcholinesterase, the highest significant inhibition 
(39.76%) was observed in multi-floral honey and the 
lowest result (3.06%) was obtained for honeydew honey. 
One honey did not show any inhibition for this enzyme 
(Baranowska-Wojcik et al. 2020).
EFFECTS OF HONEY ON MEMORY IMPAIRMENT 
Animal models of memory impairment have been 
established to investigate potential therapeutics for 
neurodegenerative disease. From the literature search, 
two studies elucidated the effect of honey in memory 
impairment. Malaysian honeys, namely Tualang and 
Kelulut demonstrated improvement on the experimentally 
induced memory impairment. In the study by Wan et 
al. (2020), memory impairment was induced by LPS 
in Sprague-Dawley rats. Tualang honey demonstrated 
an improvement in spatial and recognition memory 
following LPS-induced memory impairment (Wan et al. 
2020). In another study, Arshad et al. (2020) induced 
memory impairment with HCHF diet-induced metabolic 
syndrome in Wistar rats. Kelulut honey demonstrated an 
improvement of spatial memory as indicated by the better 
performance in the Morris water maze test. Kelulut honey 
also exhibits anxiety reducing effect in the metabolic 
syndrome rat model (Arshad et al. 2020). 
DISCUSSION
The present systematic review showed a limited body 
of literature on the potential benefits of honey in 
neurodegenerative diseases. Figure 2 illustrates the 
benefits of honey in neurodegenerative diseases. 
 
Figure 2. Benefits of honey in neurodegenerative diseases. FIGURE 2. Benefits of honey in neurodegenerative diseases
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Although the protocol outlined intended to 
identify evidence of honey benefits in wider category of 
neurodegenerative diseases, only studies pertaining to 
Alzheimer’s and Parkinson’s diseases were identified. 
This could be due to the more widespread prevalence 
of these two diseases compared to other forms of 
neurodegenerative diseases such as Huntington’s disease 
and amyotrophic lateral sclerosis.
From the identified articles to be included in the data 
synthesis of the review, six studies that utilized known 
molecules found in honey in their neurodegenerative 
disease experimental model were excluded (Barros Silva 
et al. 2013; Ferreira et al. 2018; Fontanilla et al. 2011; 
Goes et al. 2018; Ha et al. 2010; Jin et al. 2015; Kurauchi 
et al. 2012; Lee et al. 2017; Liu et al. 2012; Noelker et 
al. 2005; Wang et al. 2014, 2016; Zaitone et al. 2019). 
The exclusion of these studies was in accordance with 
the exclusion criteria that exclude any study that used 
synthetic compound not originally derived from honey. 
Although frequently reported in honey, certain flavonoids 
such as pinobanksin, pinocembrin, or caffeic acid can 
also be isolated from a variety of plants such as ginger, 
coneflower, or St John’s wort. Thus, the use of synthetic 
compound not originally derived from honey might not 
represent the effect of honey in neurodegenerative diseases.
Moreover, six studies that were done on propolis 
were also excluded from the final review (Chen et al. 
2008; Hussein et al. 2017; Nanaware et al. 2017; Ni et 
al. 2017; Swamy et al. 2014; Zhu et al. 2018). Propolis is 
the building block of the honey hive that is fortified with 
resin. This might alter the properties of the propolis and 
resulted in a distinct biological effect compared to the 
honey. Thus, the two components might not be comparable 
to each other. However, considering report of the effect of 
honey in monoamine oxidase activity, study by Yildiz et 
al. (2014) was still included in the review.
Recent strategies toward the discovery of novel 
therapeutics for neurodegenerative disease can be 
categorized into four, namely protection against oxidative 
damage, attenuation of neuroinflammation, inhibition 
of neurotransmitters degrading enzymes, and protection 
against environmental factors that induce neurotoxicity. 
Despite the small amount of evidences retrieved, all 
strategies were covered in the studies included in the data 
synthesis. As a result, the evidences were comprehensive 
in terms of putting the honey into the context of 
neurodegenerative therapy but not enough to allow 
judgement on its clinical benefit. Moreover, the lack of 
any human studies supports the cautionary concern in 
interpreting honey effect on neurodegenerative diseases.  
CONCLUSION
The review showed a sparse in vitro and in vivo evidences 
on the effect of honey in neurodegenerative diseases. 
Honey confers protection against oxidative stress induced 
by hypoxia and metabolic syndrome, aluminium toxicity, 
and neuroinflammation. Honey also demonstrated potential 
ability to inhibit neurotransmitters degrading enzymes 
and restore memory impairment.
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